Dive in

We have our own point of view on the people, technologies, and conversations that will shape the future.

Tag results
Vilya
Clear all
List view Grid view
Filters

2024: The State of Generative AI in the Enterprise

The enterprise AI landscape is being rewritten in real time. As pilots give way to production, we surveyed 600 U.S. enterprise IT decision-makers to reveal the emerging winners and losers.

Our Investment in Vilya: AI-Enabled Development of a New Class of Medicines
Key Takeaways from J.P. Morgan’s 41st Annual Healthcare Conference​
2024: The State of Generative AI in the Enterprise

The enterprise AI landscape is being rewritten in real time. As pilots give way to production, we surveyed 600 U.S. enterprise IT decision-makers to reveal the emerging winners and losers.

November 20, 2024Tim Tully, Joff Redfern and Derek Xiao
Our Investment in Vilya: AI-Enabled Development of a New Class of Medicines

Predictive and generative AI are entering many new applications. At Menlo Ventures, we are especially excited about applications for AI in drug discovery and development, specifically when new technology can directly address a major unmet need.

June 4, 2024Johnny Hu, Ph.D. and Greg Yap
Key Takeaways from J.P. Morgan’s 41st Annual Healthcare Conference​

For those in healthcare, JPM provides the unofficial kickoff to every new year with a chance to recap the year before and inform our view on the year ahead.

February 13, 2024Greg Yap, Johnny Hu and Ph.D.
loader.svg